Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | TYK2 | P29597 | 2/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.30 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.30 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.30 |
| ▸ | TAOK1 | Q7L7X3 | 4/20 | 0.30 |
| ▸ | MINK1 | Q8N4C8 | 4/20 | 0.30 |
| ▸ | PRKD2 | Q9BZL6 | 4/20 | 0.30 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.30 |
| ▸ | CSNK1G2 | P78368 | 3/20 | 0.30 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2639622 | 0.83 | BRAF (0.43) | BRAFSYKACVR1JAK2TYK2 | |
| SCHEMBL2640189 | 0.83 | BRAF (0.40) | BRAFACVR1EGFR | |
| SCHEMBL13200107 | 0.82 | BRAF (0.44) | BRAFACVR1JAK2TYK2JAK1 | |
| SCHEMBL2640080 | 0.81 | BRAF (0.40) | BRAFACVR1MKNK1 | |
| SCHEMBL2957753 | 0.81 | BRAF (0.38) | BRAFACVR1PRKD3MAP4K4MAPK8 | |
| SCHEMBL2639939 | 0.81 | BRAF (0.38) | BRAFACVR1 | |
| SCHEMBL2639692 | 0.81 | BRAF (0.38) | BRAFACVR1 | |
| SCHEMBL2639843 | 0.80 | BRAF (0.41) | BRAFACVR1 | |
| SCHEMBL2959510 | 0.80 | BRAF (0.41) | BRAFACVR1PRKD3MAP4K4MAPK8 | |
| SCHEMBL2969314 | 0.79 | BRAF (0.41) | BRAFJAK2TYK2JAK1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4792126-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| EP-2183243-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | Pfizer Inc. (US) | 2010-05-12 | — | — | EP | claimed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | claimed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2183243-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | Pfizer Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | BRAF, RAF1, NRAS | BRAF 1/4885SYK 936/4885ACVR1 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.